Logo

AGL

Agilon Health, Inc.

AGL

Agilon Health, Inc. • NYSE
$0.65 ▼ -1.99% (-0.01)
Market Cap $269.86 M
52w High $6.08
52w Low $0.51
Dividend Yield 0%
P/E -0.83
Volume 4.28M
Outstanding Shares 414.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.435B ▲ $52.106M ▼ $-110.207M ▼ -7.678% ▼ $-0.266 ▼ $-101.27M ▼
Q2-2025 $1.395B ▼ $63.6M ▼ $-104.37M ▼ -7.482% ▼ $-0.25 ▼ $-95.417M ▼
Q1-2025 $1.533B ▲ $72.832M ▲ $12.112M ▲ 0.79% ▲ $0.03 ▲ $6.699M ▲
Q4-2024 $1.522B ▲ $69.845M ▲ $-105.79M ▲ -6.949% ▲ $-0.26 ▲ $-96.605M ▲
Q3-2024 $1.451B $69.341M $-117.615M -8.106% $-0.29 $-109.182M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $310.854M ▼ $1.596B ▼ $1.29B ▼ $306.077M ▼
Q2-2025 $327.001M ▼ $1.713B ▼ $1.304B ▼ $408.929M ▼
Q1-2025 $368.766M ▼ $1.933B ▲ $1.433B ▲ $500.254M ▲
Q4-2024 $405.597M ▲ $1.734B ▼ $1.263B ▼ $470.952M ▼
Q3-2024 $398.556M $2.091B $1.517B $574.872M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-110.207M ▼ $-18.154M ▲ $18.658M ▼ $-236K ▲ $268K ▼ $-21.329M ▲
Q2-2025 $-104.37M ▼ $-35.085M ▼ $70.458M ▲ $-2.58M ▼ $32.793M ▲ $-38.335M ▲
Q1-2025 $12.112M ▲ $-31.987M ▼ $-23.089M ▼ $-161K ▼ $-55.237M ▼ $-42.87M ▼
Q4-2024 $-105.79M ▲ $16.419M ▲ $23.673M ▼ $-22K ▲ $40.07M ▲ $3.996M ▼
Q3-2024 $-126.846M $-7.703M $46.563M $-1.406M $37.454M $6.656M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Medical Services
Medical Services
 $4.60Bn ▲$1.53Bn ▼$1.39Bn ▼$1.43Bn ▲
Other Operating
Other Operating
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Agilon’s income statement tells a story of very rapid growth but persistent losses. Revenue has expanded sharply every year since before the IPO, showing the model is scaling and the company is winning more business with senior-focused primary care groups. However, gross profits are thin and operating costs remain high, so the company is still loss-making at the operating and net income levels. Losses were largest right around the IPO and have since narrowed somewhat on a per‑share basis, but they remain material. The key financial question is whether the business can keep growing while improving its medical cost performance and overhead efficiency enough to eventually move from growth-at-a-loss to growth-with-profitability.

Balance Sheet

Balance Sheet The balance sheet is relatively light on debt and still supported by positive shareholder equity, but the cushion has been shrinking. Total assets have been broadly stable in recent years, while cash levels are now much lower than right after the IPO, when the company raised a large pool of funds. Debt is modest, which reduces financial risk, yet ongoing losses have been steadily eating into equity. Overall, the balance sheet is not stressed today, but it does not have unlimited room for prolonged losses without either improved cash generation or new capital over time.

Cash Flow

Cash Flow Cash flow trends mirror the income statement: the company consistently spends more cash than it generates from operations. Operating cash flow has been negative each year, though the shortfall has modestly improved versus the early post‑IPO period. Capital spending is relatively small, so the bulk of the cash burn is tied to funding the operating model and growth, not large physical investments. Free cash flow remains negative, which means the business is still in an investment and scale‑up phase and relies on its existing cash base (and potentially future funding) to support expansion until it can reach cash break-even.

Competitive Edge

Competitive Edge Agilon is positioned as a specialist in value‑based care for seniors, particularly within Medicare Advantage, which is a structurally growing part of the U.S. healthcare market. Its model centers on deep, long‑term partnerships with primary care groups, where Agilon provides technology, capital, analytics, and contracting expertise, while physicians retain their independence. Multi‑decade partnership agreements and a growing network of leading physician groups create relationship depth and some network effects that are not easy to copy. At the same time, this is a competitive and heavily regulated space, with pressure from other value‑based platforms, payors, and health systems. The company’s edge will depend on its ability to demonstrate better outcomes and cost control than alternatives, while adapting to changes in Medicare and value‑based payment rules.

Innovation and R&D

Innovation and R&D Innovation is at the core of Agilon’s strategy. Its Total Care Model is built around a cloud‑based data and AI platform that aggregates clinical, claims, and patient information to give doctors a much fuller picture of their senior patients. The focus is on using analytics to anticipate risk, guide preventive care, and manage high‑cost, complex patients more effectively. Beyond technology, Agilon supports partners with capital, specialized clinical programs, and centralized payor contracting. Future value will likely come from deepening its AI and predictive tools, refining clinical programs, and expanding into new markets and payment models. These efforts are mainly embedded in operating expenses rather than traditional R&D line items, but they are core to the company’s long‑term differentiation.

Summary

Agilon combines strong top‑line growth and an innovative value‑based care platform with clear financial and execution risks. The business is scaling quickly in a growing Medicare Advantage and senior-care market, supported by a differentiated, physician‑centric partnership model and a data‑heavy technology backbone. However, the company is still operating at a loss, consuming cash, and seeing its equity cushion gradually reduced, even as it keeps debt low. The path forward hinges on proving that its model can consistently lower medical costs, improve margins, and turn growth into sustainable profitability while navigating regulatory shifts and intense competition in value‑based healthcare.

NEWS

November 29, 2025 · 11:00 PM UTC

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL) in Excess of $100K, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Read more

November 27, 2025 · 10:02 AM UTC

Rosen Law Firm Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL

Read more

November 26, 2025 · 4:04 PM UTC

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL

Read more

November 24, 2025 · 4:03 PM UTC

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation – AGL

Read more

November 21, 2025 · 9:08 PM UTC

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL

Read more